Immunoglobulin News and Research

RSS

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

Seropositive partners increase risk of COVID-19 but not obstetric complications in pregnant women

While earlier studies have shown the significance of serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pregnant women, their partners have largely been excluded. Now, a new Danish study published on the preprint server medRxiv in September 2020 reports the impact of serologic testing in both pregnant women and their partners, as well as their newborns.

17 Sep 2020

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Candidate monoclonal antibody shows hope as COVID-19 treatment

Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 Sep 2020

Patients with more severe SARS-CoV-2 infection exhibit larger antibody response

Researchers in the United States have found that individuals who develop more severe disease following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a larger antibody and memory B cell response during both acute infection and convalescence.

15 Sep 2020

Tiny antibody component shows high potency in SARS-CoV-2 animal models

University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19.

14 Sep 2020

Toyonaka Municipal Hospital reports successful control of COVID-19

Researchers at Toyonaka Municipal Hospital in Japan have shown that the rate of subclinical infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among staff at the hospital is no higher than among the general population in the same area.

14 Sep 2020

India's whole-virion inactivated SARS-CoV-2 vaccine shows promise

Researchers in India have conducted a preclinical study demonstrating the safety and efficacy of a new candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

13 Sep 2020

Seroconversion marks recovery from COVID-19

Nine months into the COVID-19 pandemic, scientists are still seeking to understand the protective immunity that develops against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the increasing need for serological tests in epidemiology, their clinical value has not been fully established. A new paper published in the Journal of Medical Virology in September 2020 describes the relationship of COVID-19 disease symptoms with the serological status over time.

11 Sep 2020

Researchers explore IgA response to SARS-CoV-2

A new study published on the preprint server bioRxiv* and conducted by researchers from The Rockefeller University in New York examined the role of IgA antibodies in preventing SARS-CoV-2 infection. In this study, the team analyzed the IgA response to SARS-CoV-2 infection in 149 individuals.

10 Sep 2020

Allergic immune response against bacteria is not pathological but protective

Allergy is one of the most common diseases in Europe, it is estimated that more than 150 million Europeans suffer from recurring allergies and by 2025 this could have increased to half of the entire European population.

9 Sep 2020

MIS-C linked to COVID-19 damages children's hearts

Multisystem inflammatory syndrome in children (MIS-C), believed to be linked to COVID-19, damages the heart to such an extent that some children will need lifelong monitoring and interventions, said the senior author of a medical literature review published Sept. 4 in EClinicalMedicine, a journal of The Lancet.

5 Sep 2020

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

The COVID-19 pandemic is still creating economic and health-related impact over the world. A new study published on the preprint server bioRxiv in August 2020 shows that a gp96-Ig-secreting vaccine candidate based on the expression of full-length spike protein generates a potent T cell response.

26 Aug 2020

Identifying COVID-19 host genes using symptom-based predictions

A recent study published on the preprint server bioRxiv* in August 2020 shows that symptom-based prediction of the diagnosis can help identify host genes that are responsible for part of this variability.

26 Aug 2020

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.

25 Aug 2020

High SARS-CoV-2 antibody seroprevalence, low mortality at Austrian COVID-19 epicenter

Now, a new study reported on the preprint server medRxiv* in August 2020 describes a high seroprevalence in an Austrian ski resort, which is considered to be the source of the European outbreak.

25 Aug 2020

Study reveals protective potential of all three major immunoglobulin isotypes against SARS-CoV-2

In a recent medRxiv preprint paper, researchers from Mount Sinai in New York showed that all three major immunoglobulin isotypes (IgM, IgG, and IgA) produced by our immune cells were capable of mediating neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, neutralization titers correlated much better with binding levels of IgM and IgA1 than IgG.

24 Aug 2020

DNA nanoswitches may provide an inexpensive platform to rapidly detect emerging viruses

Programmable DNA nanoswitches that bind to viral RNA in human body fluids may provide an inexpensive platform to rapidly detect a wide variety of emerging viruses, including SARS-CoV-2, according to a new study.

21 Aug 2020

Macaques show low neutralizing antibody and cellular immune response to SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 presents a cynomolgus macaque model that develops symptomatic SARS-CoV-2 infection in a mild form, with low or no antibody responses, making it suitable to study human responses to vaccines and drugs targeting the virus.

21 Aug 2020

New SARS-CoV-2 vaccine effective in macaques

Researchers from the biotechnology company Novavax in Gaithersburg, Maryland, have developed a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that successfully induces immunogenicity and protection against the virus in macaques.

20 Aug 2020

Immunoglobulin News and Research

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

Seropositive partners increase risk of COVID-19 but not obstetric complications in pregnant women

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

Candidate monoclonal antibody shows hope as COVID-19 treatment

Patients with more severe SARS-CoV-2 infection exhibit larger antibody response

Tiny antibody component shows high potency in SARS-CoV-2 animal models

Toyonaka Municipal Hospital reports successful control of COVID-19

India's whole-virion inactivated SARS-CoV-2 vaccine shows promise

Seroconversion marks recovery from COVID-19

Researchers explore IgA response to SARS-CoV-2

Allergic immune response against bacteria is not pathological but protective

MIS-C linked to COVID-19 damages children's hearts

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

Identifying COVID-19 host genes using symptom-based predictions

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

High SARS-CoV-2 antibody seroprevalence, low mortality at Austrian COVID-19 epicenter

Study reveals protective potential of all three major immunoglobulin isotypes against SARS-CoV-2

DNA nanoswitches may provide an inexpensive platform to rapidly detect emerging viruses

Macaques show low neutralizing antibody and cellular immune response to SARS-CoV-2

New SARS-CoV-2 vaccine effective in macaques

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News